CELAC and European consortium for a personalized medicine approach to Gastric Cancer (LEGACy)

CELAC and European consortium for a personalized medicine approach to Gastric Cancer (LEGACy) - LEGACY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48300

Enrollment

400

Registered

2019-11-19

Start date

2020-02-10

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer stomach cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Subjects >18 years old from IPATIMUP, INCAN, VUMC, PUC, VHIO, IAF, INCLIVA and GENPAT centres. Has given and signed the IC to participate in this study. With a gastroscopy indication due to the high diagnostic suspicion of GC as part of the study of the disease and PT-INR/PTT

Exclusion criteria

Exclusion criteria: Patients diagnosed with GC from other centres/ countries not participating in this proposal. Subjects from a different geographic area from the cases Patients unable to give IC

Design outcomes

Primary

Measure	Time frame
The primary aim of the LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention in EU and CELAC populations participating in this Project based on an omics integrative epidemiology conceptual model as a strategy to be extended worldwide.	—

Secondary

Measure	Time frame
1. Implement a personalized medicine strategy at the first level of prevention: establish coordinated work targeted at the general public based on two pillars: a) improving educational material for the lay population on the risk factors of GC, b) creating a hospital-based registry for H. pylori treated patients including a report on therapeutic resistance, to assist in the update the protocols with effective eradication therapies. 2. Improve early GC detection through a personalized medicine strategy at the second level of prevention: educating the lay population on the signs and symptoms of GC, facilitate access to endoscopy, by implementing specific measures adapted to each centers* characteristics and needs. Furthermore, implement a prospective hospital-based GC registry that will facilitate data collection and analysis on the different causes of GC diagnosis delay, and thus aid in planning health strategies at the second level of intervention. 3. Improve GC treatment approach through the stratification of patients for personalized medicine therapies. A therapeutic approach to GC based on current histological and image criteria (Tumor Node Metastasis -TNM- stage) is insufficient. Molecular landscape, complex patient history, histopathological features of the tumors (including tissue biomarkers), environmental factors, together with personal microbiome and immune landscape must contribute to the development of new therapies and ultimately patient treatment and care. LEGACy aims to improve the current knowledge on each of these aspects of the disease and treatment and thus deliver high-risk group identification through the design of a cost-effective algorithm. 4. Analyze regional variations in respect to GC among the EU-CELAC populations. Identify regional differences based on behavioral, socioeconomic, educational and belief structure, as well as the healthcare policy backgrounds and the socio-economic strata of each country.	—

Measure

Time frame

1. Implement a personalized medicine strategy at the first level of prevention: establish coordinated work targeted at the general public based on two pillars: a) improving educational material for the lay population on the risk factors of GC, b) creating a hospital-based registry for H. pylori treated patients including a report on therapeutic resistance, to assist in the update the protocols with effective eradication therapies. 2. Improve early GC detection through a personalized medicine strategy at the second level of prevention: educating the lay population on the signs and symptoms of GC, facilitate access to endoscopy, by implementing specific measures adapted to each centers* characteristics and needs. Furthermore, implement a prospective hospital-based GC registry that will facilitate data collection and analysis on the different causes of GC diagnosis delay, and thus aid in planning health strategies at the second level of intervention. 3. Improve GC treatment approach through the stratification of patients for personalized medicine therapies. A therapeutic approach to GC based on current histological and image criteria (Tumor Node Metastasis -TNM- stage) is insufficient. Molecular landscape, complex patient history, histopathological features of the tumors (including tissue biomarkers), environmental factors, together with personal microbiome and immune landscape must contribute to the development of new therapies and ultimately patient treatment and care. LEGACy aims to improve the current knowledge on each of these aspects of the disease and treatment and thus deliver high-risk group identification through the design of a cost-effective algorithm. 4. Analyze regional variations in respect to GC among the EU-CELAC populations. Identify regional differences based on behavioral, socioeconomic, educational and belief structure, as well as the healthcare policy backgrounds and the socio-economic strata of each country.

—

Countries

Netherlands

Outcome results